As a followup to the recent Senate Finance Committee hearing on drug pricing, Sen. Steve Daines (R-Mont.) has asked chief executives of two drug makers to explain discrepancies in their responses to a question about withholding samples from generic rivals.

Daines raised the issue at the Feb. 26 hearing over concerns about unfair competition and the effect on drug prices. Generic companies need samples to develop copycat medicines and sometimes run tests to show a product is bioequivalent in order to win regulatory approval.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy